Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ.
Division of Cardiology, Lehigh Valley Hospital, Allentown, PA.
Mayo Clin Proc. 2018 Apr;93(4):436-444. doi: 10.1016/j.mayocp.2017.11.022. Epub 2018 Feb 10.
To evaluate outcomes of routine invasive strategy (RIS) compared with selective invasive strategy (SIS) in elderly patients older than 75 years with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
We systematically searched databases for randomized controlled trials (RCTs) between January 1, 1990, and October 1, 2016, comparing RIS with SIS for elderly patients (age>75 years) with NSTE-ACS. Random effects meta-analysis was conducted to estimate odds ratio (OR) with 95% CIs for composite of death or myocardial infarction (MI), and individual end points of all-cause death, cardiovascular (CV) death, MI, revascularization, and major bleeding.
A total of 6 RCTs with 1887 patients were included in the final analysis. Compared with an SIS, RIS was associated with significantly decreased risk of the composite end point of death or MI (OR, 0.65; 95% CI, 0.51-0.83). Similarly, RIS led to a significant reduction in the risk of MI (OR, 0.51; 95% CI, 0.40-0.66) and need for revascularization (OR, 0.31; 95% CI, 0.11-0.91) compared with SIS. There were no significant differences between RIS and SIS in terms of all-cause death (OR, 0.85; 95% CI, 0.63-1.20), CV death (OR, 0.84; 95% CI, 0.61-1.15), and major bleeding (OR, 1.96; 95% CI, 0.97-3.97).
In elderly patients older than 75 years with NSTE-ACS, RIS is superior to SIS for the composite end point (death or MI), primarily driven by reduced risk of MI.
评估常规有创策略(RIS)与选择性有创策略(SIS)在年龄>75 岁非 ST 段抬高型急性冠脉综合征(NSTE-ACS)患者中的疗效。
我们系统检索了 1990 年 1 月 1 日至 2016 年 10 月 1 日期间的随机对照试验(RCT)数据库,比较了 RIS 与 SIS 对年龄>75 岁的 NSTE-ACS 患者的疗效。采用随机效应荟萃分析估计死亡率或心肌梗死(MI)复合终点、全因死亡、心血管(CV)死亡、MI、血运重建和大出血的个体终点的比值比(OR)及其 95%置信区间(CI)。
最终纳入了 6 项 RCT 共 1887 例患者。与 SIS 相比,RIS 显著降低了死亡或 MI 的复合终点风险(OR,0.65;95%CI,0.51-0.83)。同样,与 SIS 相比,RIS 也显著降低了 MI(OR,0.51;95%CI,0.40-0.66)和血运重建的风险(OR,0.31;95%CI,0.11-0.91)。RIS 与 SIS 相比,在全因死亡(OR,0.85;95%CI,0.63-1.20)、CV 死亡(OR,0.84;95%CI,0.61-1.15)和大出血(OR,1.96;95%CI,0.97-3.97)方面无显著差异。
在年龄>75 岁的 NSTE-ACS 患者中,与 SIS 相比,RIS 更有利于复合终点(死亡或 MI),主要是因为 MI 风险降低。